Projects we fund

Overview

Immunotherapy is playing an increasingly important role in the treatment of childhood cancers, and this project is focused on a protein called B7H3, which is present in a number of cancers, including neuroblastoma and the brain tumour known as DIPG. B7H3 helps cancer cells grow and multiply, and also reduces the effectiveness of chemotherapy. Dr Kathleen is aiming to make special antibodies, which will recognise and attach themselves to B7H3, which is only present on diseased cells, not on healthy ones. These antibodies will act as a sort of magnet and attract immune cells, which will then go to work on the cancer cells while also improving the body’s own natural defence mechanisms.

What difference will this project make?

The protein known as B7H3 is present on a number of different types of cancer, including neuroblastoma and DIPG. If Dr Kathleen’s work is successful, the infrastructure at UCL’s Institute of Child Health means that the therapy could be rapidly taken forward from the lab towards the point where it can be tested in young people. Another key aim of this grant, and our studentship scheme in general, is the development of Dr Kathleen’s research expertise. Through this grant and the research she is carrying out she will obtain a master’s degree and then a PhD. This will enable her to develop a dual career that combines research and clinical practice so that she can continue to research and develop exciting new treatments for young people living with cancer.